Vol.52, No.2, Dec. 2024Current status and challenges in pharmaceutical medicine / Evaluation of COVID-19 Vaccine Safety
Vol.52, Suppl 40, 2024The Second Annual Conference of the Society for Health Data Science
Vol.52, No.1, Jul. 2024「ヘルシンキ宣言」2024年改訂に向けて－「グローバルヘルスのための倫理的イノベーション」より
Cornerstone of next generation research and development: Overcoming COVID-19 pandemic /
For the 2024 revision of the Declaration of Helsinki: From the “Ethical innovation for global health”
Vol.51, No.3, Feb. 2024～群馬大学大学院 医理工レギュラトリーサイエンス学環設置 プレシンポジウム～
Data science from the view of the Regulatory Science and Open Science: Theory and human resource development
～Pre-symposium for the establishment of Interfaculty Initiative in Regulatory Science of Biomedical Science and Engineering, Gunma University～
Vol.51, Suppl 39, 2024Patient involvement in the development, regulation and safe use of medicines: Report of the CIOMS Working Group XI
Vol.51, No.2, Oct. 2023The First Annual Conference of the Society for Health Data Science
Vol.51, No.1, Jul. 2023Frontier of Clinical Medicine as Predictive Science
Vol.50, No.4, Feb. 2023Data science and research ethics to achieve the SDGs: The future of regulatory science and academic journalss
Vol.50, No.3, Dec. 2022The 1st Bioethics Seminar Development of bioethics and SDGs / The 2nd Bioethics Seminar Patient-oriented Bioethics
Vol.50, No.2, Oct. 2022LHSI - the first anniversary commemoration symposium
Vol.50, No.1, Jun. 2022The current state of the legal framework for research involving humans: International and domestic analysis
Vol.49, No.3, Feb. 2022COVID-19パンデミックを乗り超える：科学・社会・医療を繋ぐ課題と展望（第2回）
The 12th Annual Meeting of the Japanese Association of Pharmaceutical Medicine 2021 /
Perspectives for overcoming the COVID-19 pandemic: Science, society and medicine: the 2nd session
Vol.49, Suppl XXXVIII 2021COVID-19 and bioethics Part 3: Pandemic and research ethics－Democracy, placebo and post-trial access
Vol.49, No.2, Sep. 2021Research Meeting and Webinar on Cutaneous Leishmaniasis (CL):
Research and development for neglected diseases and associated social issues
Vol.49, No.1, May 2021The effects on sales volume share of value-added generic drugs
～A complex analysis of pharmaceutical companies’ motivation to develop value-added generic drugs～
Vol.48, Suppl XXXVII 2021The real status of Japan’s “2040 issue”: The role and mission of TRI / Road to Learning Health Society
Vol.48, No.3, Dec. 2020Perspectives for overcoming the COVID-19 pandemic: Science, society, and medicine
Vol.48, No.2, Oct. 2020Medical Innovation and Longevity (the 2nd session): “Centenarian heart” and “cancer genome medicine”
Vol.48, No.1, Jun. 2020第120回くすり勉強会 国際共同研究の倫理：ブラジルからの視座
Presidential Symposium in the 40th Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics, 2019
International Collaborative Research and New Trends of Research Ethics /
The 120th Pharmaceutical Study Group Meeting Ethics of international collaborative research: Perspectives from Brazil
Vol.47, No.3, Feb. 2020IRB委員のリスク・ベネフィット評価の方法論と審査結果の基準／
韓国と日本のIRB／倫理審査における「一般の立場」の委員の役割と経験
The 2nd meeting on the future perspective of the pharmaceutical industry utilizing Real-World Data and Digital Health /
Methodology of risk-benefit assessment and standardization of voting options in IRBs /
The mission and experience of layperson members of the IRB/EC in Korea and Japan
Vol.47, No.2, Nov. 2019The 19th International Conference in Pharmaceutical Medicine (ICPM) 2018 (Tokyo): The Future of Medicines Development
Vol.47, Suppl XXXVI 2019Achievements of AMED and exponential research and development in Japan /
The Steps to Disease Control: University’s mission to establish an R&D ecosystem
Vol.47, No.1, Jun. 2019Product development and innovation in the era of Digital Health / Academia-initiated product development and the Clinical Trials Act
Vol.46, No.3･4, Feb. 2019科学技術社会論学会第16回年次研究大会セッション「製品開発と研究倫理：過去・現在・未来」より
Clinical trial data sharing; Clinical Trial Act in Japan / FDA・EMA Guidance on botanical/herbal product development／
From the symposium titled “Product development and research ethics: the past, present and future”at the 16th annual meeting of the Japanese Society for Science and Technology Studies
Vol.46, No.2, Sep. 2018アカデミア発シーズ開発最前線・日米臨床試験規制の検討
Perspectives toward global health: Life-saving portfolios ／
Front line of academia-initiated product development / Regulatory considerations in Japan and the US
Vol.46, No.1, Jun. 2018生命倫理と研究倫理の過去・現在・未来（第6回）
Actual status and future perspective of clinical trial data sharing－Ethics, credibility, and available technology for trial data linkage－ /
The past, present and future of bioethics and research ethics (Part VI)
Vol.45, No.4, Feb. 2018Paradigms shift of drug discovery, development and lifetime management (Part II) /
The past, present and future of bioethics and research ethics (Part V)
Vol.45, No.3, Nov. 2017生命倫理と研究倫理の過去・現在・未来（第4回）
Partnership for NTDs drug discovery originated in Japan /
The past, present and future of bioethics and research ethics (Part IV)
Vol.45, No.2, Aug. 20175th World Centenarian Initiative International Symposium on Stroke /
The past, present and future of bioethics and research ethics (Part III)
Vol.45, No.1, Apr. 2017ASIA ARO Network Workshop
The past, present and future of bioethics and research ethics (Part II) / 2nd Taiwan-Japan Academic Research Organization Workshop / ASIA ARO Network Workshop
Vol.44, No.4, Feb. 20174th World Centenarian Initiative 第2回 弘前医療技術イノベーションシンポジウム／
分子イメージングバイオマーカーの世界標準化に向けて
Overcoming neurodegenerative diseases by innovative therapeutic developments /
4th World Centenarian Initiative 2nd Medical Technological Innovation Symposium in Hirosaki /
Toward the global standardization of molecular imaging biomarkers
Vol.44, No.3, Dec. 20163rd World Centenarian Initiative ALS病治療戦略国際シンポジウム
Paradigms shift of drug discovery, development and lifetime management /
Taiwan-Japan Academic Research Organization Workshop 2015 /
3rd World Centenarian Initiative International Symposium on Amyotrophic Lateral Sclerosis
Vol.44, No.2, Jun. 2016The 14th Setouchi International Conference on Clinical Trials /
The past, present and future of bioethics and research ethics (Part I)
Vol.44, No.1, Apr. 2016第30回 日本国際保健医療学会 学術大会2015 グローバルヘルスの潮流
2nd World Centenarian Initiative International Symposium on Alzheimer's Diseases Prevention Strategy /
The 30th Japan Association for International Health Congress 2015 Trend in global health and infectious diseases
Vol.43, No.2, Jan. 2016（難治性疾患実用化研究・腎疾患実用化研究・慢性の痛み解明研究）成果報告会 難病制圧に向けて／
文部科学省 橋渡し研究加速ネットワークプログラム がん統合戦略会議
Rare and Intractable Diseases Translational Research Conference 2014 Toward the New Horizon of Rare Disease /
Consolidated strategic meeting for cancer research and management in disruptive innovation era
Vol.43, Suppl XXXV 2015平成26年度成果報告会
Public Debriefing Session 2014
Vol.43, No.1, Aug. 2015文部科学省 橋渡し研究加速ネットワークプログラム 第2回海外TRセンターワークショップ／
日本薬学会 第135年会 シンポジウム 日本発 顧みられない熱帯病治療薬開発への挑戦
The 33rd Aso-Kujyu Conference on Clinical Pharmacology /
Consolidated Strategic Meeting on Development of Next-generation Cancer Molecular-targeted Therapy /
The 2nd Translational Research Center Workshop /
The challenge of developing new treatments for NTDs originating from Japan
Vol.43, Suppl XXXIV 2015Moving beyond the Comfort Zone
Vol.42, Suppl XXXIII 2014Public Debriefing Session 2013
Vol.42, No.2, Oct. 2014医療イノベーション・マネジメントと申請データ標準化の動向
The 12th Setouchi International Conference on Clinical Trials /
The 32nd Aso-Kujyu Conference on Clinical Pharmacology /
Medical Innovation Management and the trend of data standardization
Vol.42, No.1, Jul. 2014文部科学省 橋渡し研究加速ネットワークプログラム 海外TRセンターワークショップ
Overcoming neuronal system refractory diseases: The current situation and future prospects for the development of innovative therapies for spinal cord injury / Translational Research Center Workshop
Vol.42, Suppl XXXII 2014Next Steps and Actions as one of the Leading Countries
Vol.41, No.4, Feb. 2014特集1：臨床研究の信頼性を考える／特集2：臨床研究の制度と信頼性に関する海外情勢
Reformation of clinical research and medical innovation policies in Japan: Challenges and opportunities /
Reflecting on the credibility of investigator-initiated clinical trials /
The regulations and credibility of investigator-initiated clinical trials in the United States and Europe
Vol.41, No.3, Jan. 2014The 3rd International Symposium of Early Stage Clinical Trial /
Urgent special topic Opinions on the concept paper of integrating epidemiological and clinical guidelines
Vol.41, No.2, Oct. 2013ヘルシンキ宣言改訂専門家会議（東京）／精神疾患に対する脳神経外科治療
The 11st Setouchi International Conference on Clinical Trials /
Expert Conference on the Revision of the Declaration of Helsinki in Tokyo / Neurosurgical treatment of psychiatric disorders
Vol.41, No.1, Jul. 2013平成24年度成果報告会
Public Debriefing Session 2012
Vol.40, No.2, Mar. 2013第2回早期臨床試験国際会議／第31回臨床薬理阿蘇九重カンファレンス
Dawning of the “Sunshine Act”: Towards a new phase of conflict of interest management /
The 2nd International Symposium of Early Stage Clinical Trial / The 31st Aso-Kuju Conference on Clinical Pharmacology
Vol.40, No.1, Oct. 2012New trend of clinical trial and clinical research / The 10th Setouchi International Conference on Clinical Trials
Vol.40, Suppl XXXI 2012平成23年度成果報告会
Public Debriefing Session 2011
Vol.40, Suppl XXX 2012Innovative Strategies for Enhancing Regional Drug Development as a Global Drug Development
Vol.39, No.3, Mar. 2012厚生労働省治験中核病院 臨床研究基盤整備事業 治験中核病院・拠点医療機関連携セミナー
First-in-Human試験セミナー＆ワークショップ
The 30th Aso-Kuju Conference on Clinical Pharmacology / First-in-Human Trial Seminar & Workshop
Vol.39, No.2, Oct. 2011平成22年度成果報告会／
平成22年度厚生労働科学研究費補助金（医療技術実用化総合研究事業）
早期臨床試験国際会議 in Beppu
Public Debriefing Session 2010 / International symposium of early stage clinical trial in Beppu
Vol.39, No.1, Jun. 2011The status and perspectives of compensation for research-related injuries
Vol.39, Suppl XXIX 2011Innovative Strategies for Future Objectives
Vol.38, No.4, Mar. 2011The international conference in Matsuyama for promoting global clinical new drug developments / Consensus meeting for adipose tissue derived stem cell therapy
Vol.38, No.3, Oct. 2010第8回トランスレーショナルリサーチ研修会／平成21年度成果報告会
The 8th Translational Research Educational Program / Public Debriefing Session 2009
Vol.38, No.2, Sep. 2010The use of Bayesian statistics in clinical trials
Vol.38, No.1, Jun. 2010ICH-S7B, E14: The notifications in Japan and their impact on new drug development
Vol.37, Suppl XXVIII 2010Significance of Asian Studies in Simultaneous Global Clinical Trials
Vol.37, No.2, Feb. 2010The international meeting for promotion of global clinical development in Tokyo: What is the true endpoint of global clinical trials and how do we manage?
Vol.37, No.1, Oct. 200910th annual meeting of the Japan Society of Clinical Pharmacological Studies / The 27th Aso-Kujyu Conference on Clinical Pharmacology
Vol.37, Suppl XXVII 2009Learning from Experience and New Challenges fot the Future
Vol.36, Suppl XXVI 2009Clinical science：Principles and practice─Science, law and humanity─
Vol.36, No.3, Apr. 2009Microdosing clinical trials of biologics
Vol.36, No.2, Dec. 2008Drug development and Medical Research Act in the Netherlands
Vol.36, No.1, Aug. 2008The symposium on Deep Brain Stimulation (DBS) therapy for Psychiatric Disorders
At the 47th meeting of the Japan Society for Stereotactic and Functional Neurosurgery
Vol.35, No.3, Jun. 2008J-CLIPNET - Bases for early phase global clinical development
Vol.35, No.2, Dec. 2007The international meeting for promotion of global clinical development in Beppu
Vol.35, No.1, Sep. 2007A handbook for IRB members
Vol.35, Suppl XXV 2007Japan's Critical Path Opportunities
Vol.34, No.3, May 2007Safety information: reporting, dissemination, and analysis
Vol.34, No.2, Apr. 2007What is the future of obstetric medicine?
Vol.34, No.1, Feb. 2007CIOMS Guidelines for Biomedical Research
Vol.34, Suppl XXIV 2006What is the TGN 1412 case ?
Vol.33, No.3, Oct. 2006Basis of translational research: Academia-oriented clinical trials and new drug and medical technology development
Vol.33, Suppl XXIII 2006Development, Evaluation and Approval of New Drugs
Vol.33, No.2, Apr. 2006Position and role of the Asian and Oceanic regions in drug development
Vol.33, No.1, Dec. 2005ARO and IRB: Business-academia collaboration
Vol.32, No.2・3, Sep. 2005Risk management of pharmaceuticals ―product management and project management―
Vol.32, Suppl XXII 2005Global Development Strategies of New Drugs
Vol.32, No.1, Apr. 2005Clinical trial registration and the issue of "Mixed health insurance"
Vol.32, Suppl XXI 2004Scientific and ethical evaluation of regenerative medicine
Focus on bone marrow and fetal stem cell clinical research
Vol.31, No.3, Sep. 2004Actual status of the new drug approval review system
Vol.31, Suppl XX 2004Forefront of New Drug Development Strategies
Vol.31, No.2, Apr. 2004The regulatory situations of clinical trials in the US, Europe and Asia
Vol.31, No.1, Dec. 2003The changing situation of clinical trials and support systems: Actual problems and how to solve them
Vol.30, No.2･3, Sep. 2003Clinical research in the "Bio-Genome Century" and the revised Pharmaceutical Affairs Law
Vol.30, Suppl XIX 2003Simultaneous, Worldwide Development Strategies
Vol.30, Suppl XVIII 2003Vol.30, No.1, Oct. 2002Quality assurance of investigator-oriented clinical research in Japan
-Current status and efforts towards future development-
Vol.29, No.2･3, May. 2002Knowledge management and knowledge sharing
Vol.29, Suppl XVII 2002Bridging Strategies and Pharmacogenomics
Vol.29, No.1, Nov. 2001Drug safety-current status and future perspectives
Vol.29, Suppl XVI 2001Clinical Evaluation of OTC Drugs and Traditional Drugs
Vol.28,Suppl XV 2001Bridging Strategies
Vol.28, No.3, Jun. 2001The 2000 revision to the Declaration of Helsinki and ethics in this era of globalization
Vol.28, No.2, Jan. 2001Support systems for clinical trials under the new GCP
Vol.28, No.1, Oct. 2000External quality assurance in clinical trials
Vol.27, Suppl XIV 2000World wide view on development and evaluation of switched and direct OTC
Vol.27, No.3, Apr. 2000Information disclosure on clinical trials and international public health
Vol.27, No.2, Dec. 1999Present Status of Clinical Trials and Supporting Systems in Three Regions (Japan, the US and Europe)
Vol.27, No.1, Sep. 1999Application of Statistical Principles for Clinical Trials
Vol.26, Suppl XIII 1999Evidence of Off-Label Use of Drug
Vol.26, No.3, Feb. 1999Vol.26, No.2, Nov. 1998Vol.26, No.1, Jul. 1998Vol.25, No.2・3, Apr. 1998Vol.25, No.1, Sep. 1997Vol.25, Suppl XII 1997Vol.24, No.2・3, May. 1997